IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

IGM Biosciences, Inc. announced that the FDA has cleared two Investigational New Drug applications for imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, enabling the initiation of Phase Ib studies in both severe systemic lupus erythematosus and severe rheumatoid arthritis.